BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Atazanavir
Drug: Ritonavir
Drug: Tenofovir (TDF)
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Drug: Famotidine (FAM)

First Posted Date: 2010-11-02

Last Posted Date: 2012-08-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT01232127

Locations: 🇬🇧
Local Institution, London, Greater London, United Kingdom

Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

Phase 4

Completed

Conditions: Irritability Associated With Autistic Disorder

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2010-10-25

Last Posted Date: 2014-05-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 215

Registration Number: NCT01227668

Locations: 🇺🇸
Childrens Specialty Gr., Pllc, Norfolk, Virginia, United States
🇺🇸
Stony Brook University School Of Medicine, Stony Brook, New York, United States
🇺🇸
Children'S Specialized Hosp, Toms River, New Jersey, United States

and more 35 locations

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: BMS-754807
Drug: letrozole

First Posted Date: 2010-10-20

Last Posted Date: 2020-08-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 77

Registration Number: NCT01225172

Locations: 🇺🇸
Oncology Care Associates, P.A., Wheaton, Maryland, United States
🇺🇸
Presbyterian Hospital Cancer Research, Charlotte, North Carolina, United States
🇺🇸
University Of Virginia Health System, Charlottesville, Virginia, United States

and more 13 locations

Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept

Phase 1

Withdrawn

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2010-10-15

Last Posted Date: 2015-09-01

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01221636

Locations: 🇺🇸
Local Institution, Austin, Texas, United States

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Dasatinib
Drug: BMS-833923

First Posted Date: 2010-10-11

Last Posted Date: 2016-06-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 33

Registration Number: NCT01218477

Locations: 🇺🇸
University Of California Medical Center, San Francisco, California, United States
🇺🇸
Ut M.D. Anderson Cancer Center, Houston, Texas, United States
🇬🇧
Local Institution, Glasgow, United Kingdom

and more 1 locations

Effect of Diltiazem on Pharmacokinetics of BMS-914392

Phase 1

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: BMS-914832
Drug: Diltiazem

First Posted Date: 2010-09-30

Last Posted Date: 2011-02-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT01211808

Locations: 🇺🇸
Pra International, Lenexa, Kansas, United States

Effect of BMS-914392 on Pharmacokinetics of Metoprolol

Phase 1

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: metoprolol
Drug: BMS-914392

First Posted Date: 2010-09-30

Last Posted Date: 2011-02-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT01211821

Locations: 🇺🇸
Pra International, Lenexa, Kansas, United States

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Phase 2

Completed

Conditions: Hepatitis B Virus

Interventions: Drug: pegIFNα-2a
Drug: PegIFN lambda
Drug: pegIFN
Drug: Entecavir

First Posted Date: 2010-09-17

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 197

Registration Number: NCT01204762

Locations: 🇺🇸
Sc Clinical Research, Inc., Garden Grove, California, United States
🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸
Office Of Sing Chan Md, Flushing, New York, United States

and more 14 locations

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

Phase 1

Terminated

Conditions: Venous Thromboembolism

Interventions: Drug: Apixaban

First Posted Date: 2010-09-06

Last Posted Date: 2017-04-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT01195727

Locations: 🇺🇸
The Toledo Children'S Hospital, Toledo, Ohio, United States
🇺🇸
Penn State Hershey Children'S Hospital, Hershey, Pennsylvania, United States
🇺🇸
Children'S Hospital Of Orange County, Orange, California, United States

and more 2 locations

Ph IIA Study (SOC +/- NS5B)

Phase 2

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: BMS-791325
Drug: Placebo
Drug: Peg-interferon alfa-2a
Drug: Ribavirin

First Posted Date: 2010-09-01

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT01193361

Locations: 🇺🇸
Options Health Research, Llc, Tulsa, Oklahoma, United States
🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy